Abstract
Suramin is an antitrypanosomal compound with confirmed efficacy against several human malignancies. It is generally assumed that its mechanism of action includes the interaction with different growth factors, unlike most of the anticancer drugs. Its anticancer activity has not been testedin vivo against squamous cell carcinoma. The purpose of this study was to assess the efficacy and toxicity of suraminin vivo andin vitro on the VX2 tumor model at therapeutic monitored plasma concentrations. We determined the pharmacokinetics of suramin in rabbits, and modelized its administration in order to obtain plasma concentrations between 150 and 300 μg/ml throughout the treatment course of 3 weeks. Under these conditions, antitumor effects of suramin were evaluatedin vivo by comparing liver tumor involvement in suramin-treated and control rabbits. Liver involvement was quantified by image analysis andin vitro effects were also determined at the same concentrations.In vivo, suramin promoted liver tumor growth significantly (p<0.05), compared to untreated controls.In vitro, suramin significantly stimulated tumor cell growth at concentrations above 200 μg/ml (p<0.01). Suramin may have stimulatory effects on tumor growth in squamous cell carcinoma at relevant plasma drug concentrations. Caution should be taken in further trials in patients with squamous cell carcinomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Myers C, Cooper M, Stein C, La Rocca R, Walther M, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich M, Cassidy J, Kohler D, Trepel J, Linehan W: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881–889, 1992
La Rocca R, Stein C, Danesi R, Jamis-Dow C, Weiss GH, Myers CE: Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicityin vitro, and clinical antitumor effect. J Clin Endocrinol Metab 71:497–503, 1990
La Rocca R, Cooper MR, Stein C, Kohler D, Uhrich M, Weinberger E, Myers CE: A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann Oncol 3:571–573
Stein CA, La Rocca RV, Thomas R, McAtee N, Myers CE: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499–508, 1989
Garrett J, Coughlin S, Niman H, Tremble PM, Giels G, Williams LT: Blockade of autocrine stimulation in simian sarcoma virus transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci USA 81:7466–7470, 1984
Klecker R, Collins J: Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography. J Liqu Chromatogr 8:1685–1696
SAS Institute Inc.SAS/STAT ® User’s Guide, version 6, Fourth Edition, Volume 2, Cary, NC: SAS Institute Inc., 1989
Cardinali M, Sartir O, Robbins KC: Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest 89:1242–1247
Morocz I, Lauber B, Schmitter D, Stahel RA:In vitro effect of suramin on lung tumour cells. Eur J Cancer 29A:245–247, 1993
Pienta K, Isaacs W, Vindivich D, Coffey DS: The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199–202, 1991
Wade T, Kasid A, Stein C, La Rocca R, Sargent ER, Gomella LG, Myers CE, Linehan WM: Suramin interference with TGF-beta inhibition of human renal cell carcinoma in culture. J Surg Res 53:195–198
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ramirez, L.H., Juliéron, M., Bonnay, M. et al. Stimulation of tumor growthin vitro andin vivo by suramin on the VX2 model. Invest New Drugs 13, 51–53 (1995). https://doi.org/10.1007/BF02614220
Issue Date:
DOI: https://doi.org/10.1007/BF02614220